XWELL Appoints Ezra Ernst as New President and Chief Executive Officer
XWELL, Inc. (Nasdaq: XWEL) has appointed Ezra T. Ernst as its new Chief Executive Officer, succeeding Scott Milford. Ernst, with over 30 years of experience, previously led XWELL brands XpresCheck® and HyperPointe™. He aims to drive growth through innovation, expansion, and technology integration across XWELL's portfolio.
Key initiatives include evolving the company's footprint in and out of airports, integrating technology across brands, and expanding services like the Traveler-based Genomic Surveillance (TGS) program with the CDC. Ernst plans to focus on geographic expansion, acquisitions, and autonomous technology to cater to tech-savvy consumers and return the company to profitability.
XWELL, Inc. (Nasdaq: XWEL) ha nominato Ezra T. Ernst come nuovo Amministratore Delegato, succedendo a Scott Milford. Ernst, con oltre 30 anni di esperienza, ha precedentemente guidato i marchi XWELL XpresCheck® e HyperPointe™. Il suo obiettivo è stimolare la crescita attraverso innovazione, espansione e integrazione della tecnologia nel portafoglio di XWELL.
Le iniziative chiave includono l'evoluzione della presenza dell'azienda dentro e fuori gli aeroporti, l'integrazione della tecnologia tra i marchi e l'espansione dei servizi come il programma di Sorveglianza Genomica Basata sul Viaggiatore (TGS) con i CDC. Ernst intende concentrarsi su espansione geografica, acquisizioni e tecnologia autonoma per soddisfare i consumatori esperti di tecnologia e riportare l'azienda alla redditività.
XWELL, Inc. (Nasdaq: XWEL) ha nombrado a Ezra T. Ernst como su nuevo Director Ejecutivo, sucediendo a Scott Milford. Ernst, con más de 30 años de experiencia, anteriormente lideró las marcas XWELL XpresCheck® y HyperPointe™. Su objetivo es impulsar el crecimiento a través de innovación, expansión e integración de tecnología en el portafolio de XWELL.
Las iniciativas clave incluyen evolucionar la huella de la empresa dentro y fuera de los aeropuertos, integrar la tecnología en todas las marcas y expandir servicios como el programa de Vigilancia Genómica Basada en Viajeros (TGS) con los CDC. Ernst planea enfocarse en expansión geográfica, adquisiciones y tecnología autónoma para atender a consumidores conocedores de la tecnología y devolver a la empresa a la rentabilidad.
XWELL, Inc. (Nasdaq: XWEL)은 Ezra T. Ernst를 새로운 CEO로 임명했습니다, Scott Milford의 후임입니다. Ernst는 30년 이상의 경험을 가지고 있으며, 이전에 XWELL 브랜드인 XpresCheck®와 HyperPointe™를 이끌었습니다. 그는 혁신, 확장 및 기술 통합을 통해 XWELL의 포트폴리오 전반에 걸쳐 성장시키는 것을 목표로 하고 있습니다.
주요 이니셔티브로는 공항 내외에서 회사의 입지를 진화시키고, 브랜드 간 기술을 통합하며, CDC와 함께 여행자 기반 유전자 감시(TGS) 프로그램과 같은 서비스를 확장하는 것입니다. Ernst는 기술에 능숙한 소비자를 대상으로 지리적 확장, 인수 합병 및 자율 기술에 집중하여 회사를 수익성으로 되돌릴 계획입니다.
XWELL, Inc. (Nasdaq: XWEL) a nommé Ezra T. Ernst comme nouveau Directeur Général, succédant à Scott Milford. Ernst, fort de plus de 30 ans d'expérience, a précédemment dirigé les marques XWELL XpresCheck® et HyperPointe™. Il vise à stimuler la croissance grâce à l'innovation, l'expansion et l'intégration technologique dans le portefeuille de XWELL.
Les initiatives clés comprennent l'évolution de l'empreinte de l'entreprise dans et en dehors des aéroports, l'intégration de la technologie entre les marques et l'expansion des services comme le programme de surveillance génomique basé sur les voyageurs (TGS) avec les CDC. Ernst prévoit de se concentrer sur l'expansion géographique, les acquisitions et la technologie autonome pour répondre aux consommateurs férus de technologie et ramener l'entreprise à la rentabilité.
XWELL, Inc. (Nasdaq: XWEL) hat Ezra T. Ernst als neuen CEO ernannt, der Scott Milford nachfolgt. Ernst, der über 30 Jahre Erfahrung verfügt, leitete zuvor die XWELL-Marken XpresCheck® und HyperPointe™. Er hat sich zum Ziel gesetzt, das Wachstum durch Innovation, Expansion und Technologieintegration in XWELLs Portfolio voranzutreiben.
Wichtige Initiativen umfassen die Weiterentwicklung der Unternehmenspräsenz in und außerhalb von Flughäfen, die Integration von Technologie über die Marken hinweg und die Erweiterung von Dienstleistungen wie das reisendenbasierte genomische Überwachungsprogramm (TGS) mit den CDC. Ernst plant, sich auf geografische Expansion, Akquisitionen und autonome Technologie zu konzentrieren, um technologisch versierten Verbrauchern gerecht zu werden und das Unternehmen wieder profitabel zu machen.
- Appointment of experienced CEO Ezra T. Ernst with over 30 years in the industry
- Successful expansion of the Traveler-based Genomic Surveillance (TGS) program with the CDC
- Planned geographic expansion and acquisitions to drive growth
- Focus on integrating technology across the company's portfolio
- Opening of new XpresSpa locations in Philadelphia International Airport and New York Penn Station
- Transition period as new CEO takes over from Scott Milford
- Implied need to return the company to profitability, suggesting current financial challenges
Strategic leadership change will drive further growth and expansion among core business units
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today announced the appoint of Ezra T. Ernst as Chief Executive Officer. Ernst succeeds Scott Milford, who will serve in a consultative role through the end of 2024.
“Ezra brings the combination of operational and strategic excellence to the position, while also having a deep understanding of the company, the industry and key partners,” said XWELL Chairman of the Board, Bruce Bernstein. “This strategic leadership change will propel XWELL forward in its next phase. I trust that Ezra will deliver purpose-driven growth for XWELL through continued innovation and expansion, ultimately returning the company to profitability. We appreciate Scott’s hard work transforming the company into what it is today.”
Ernst has a strong track record with more than 30 years of experience driving revenue, developing strategic partnerships and cultivating operational excellence. Most recently he served as CEO of XWELL brands XpresCheck® and HyperPointe™ since January 2022 and March 2020, respectively.
Ernst has successfully increased revenue and reputational awareness through his leadership of XpresCheck where he developed the Traveler-based Genomic Surveillance (TGS) program with the Centers for Disease Control and Prevention (CDC). The TGS program has expanded from a small pilot program leveraging XpresCheck’s leading COVID-19 testing program and HyperPointe’s marketing expertise to a more permanent part of the United States’ biosecurity infrastructure.
“I am excited for the opportunity to lead XWELL in the next chapter of its evolution,” said Ernst. “We are positioned for growth across our brands, and I am very confident in our people to carry through the vision and strategy we have developed.”
Ernst will build on the framework Milford created for the Company’s long-term success including XWELL’s out of airport strategy, its Naples Wax Center® acquisition, which increased the number of physical retail units and expanded innovative products and services, XpresSpa®’s tech-forward strategy and XpresCheck’s leadership in biosecurity.
In the near term, Ernst plans to evolve the Company’s current footprint in and out of the airport by further integrating technology across its portfolio. This includes the successful opening of XpresSpa at Philadelphia International Airport’s Terminal B and the upcoming launch of XpresSpa at New York Penn Station. Ernst will also continue to integrate HyperPointe to support XWELL more broadly as it seeks new marketing opportunities.
Ernst added, “I look forward to making meaningful progress through geographic expansion, acquisitions and technology, while also focusing on broadening the full potential of autonomous technology and catering to the preferences of today’s tech-savvy consumers. Thank you to the board of directors and the senior leadership team for your continued support and commitment to this company.”
For more information about this new offering, visit xwell.com.
About XWELL, Inc.
XWELL, Inc. (Nasdaq: XWEL) is a leading global wellness holding company operating multiple brands: XpresSpa®, Treat™, Naples Wax Center®, XpresCheck® and HyperPointe™.
- XpresSpa is a leading retailer of wellness services and related products, with 33 locations in 16 airports globally.
- Naples Wax Center is a group of upscale skin care boutiques, with three locations currently operating.
- XpresCheck, in collaboration with the CDC and Concentric by Ginkgo, conducts biosurveillance monitoring of inbound international flights. Operating 9 biosurveillance stations in 7 of the nation’s busiest airports, XpresCheck tests passengers and wastewater to monitor and identify new SARS-CoV-2 variants as well as other pathogens entering the USA from across the world.
- HyperPointe is a leading digital healthcare and data analytics relationship company serving the global healthcare industry.
Forward-Looking Statements
This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. Forward-looking statements relating to expectations about future results or events, including the Company’s current plans and expectations relating to the business and operations and future store openings, including but not limited to, future openings of Naples Wax Center and XpresSpa stores, are based upon information available to XWELL as of the date of this press release, and are not guarantees of the future performance of the Company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XWELL, or other matters and attributable to XWELL or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XWELL does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.
FAQ
Who is the new CEO of XWELL (XWEL)?
What is XWELL's (XWEL) strategy for future growth?
What is the Traveler-based Genomic Surveillance (TGS) program mentioned in relation to XWELL (XWEL)?
Where is XWELL (XWEL) expanding its XpresSpa locations?
